SAN DIEGO — Standard care treatments for multiple myeloma conferred markedly shorter survival benefits in real-world settings, study results presented at ASH Annual Meeting and Exposition showed.
Data from a retrospective analysis revealed that six of seven standard care regimens evaluated had significantly shorter PFS and OS in real-world clinical practice compared with their performance in registrational phase 3 randomized controlled trials.
Despite this drop in efficacy, the standard care regimens evaluated performed similarly in terms of safety under both real-world and clinical trial
